AIkido Pharma Inc. announced it has extended its previously disclosed exclusive option agreement with the University of Maryland, Baltimore for the technology set forth in Patent number 10,434,116 “Methods of Treating Coronavirus Infection.” The present invention provides methods for treating a coronavirus infection.
AIkido Extends Option to License Patented Treatment for Coronavirus
NEW YORK, Aug. 11, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) today announced it has extended its previously disclosed exclusive option agreement (“Option”) with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 “Methods of Treating Coronavirus Infection.” The present invention provides methods for treating a coronavirus infection. The initial Option for Treatment of Coronavirus was previously disclosed on March 6, 2020. The Option has been extended until December 2, 2020. All other terms and conditions of the original Option agreement remain in full force and effect.
This invention was made with government support under Grant Number AI095569 awarded by the National Institutes of Health. As result, the NIH has certain rights in the invention.
About AIkido
AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/option-for-treatment-for-coronavirus-extended-301109887.html
SOURCE AIkido Pharma Inc.
Company Codes: NASDAQ-NMS:AIKI
